Trxade Group, Inc. (MEDS)
Market Cap | 47.51M |
Revenue (ttm) | 16.82M |
Net Income (ttm) | -719,096 |
Shares Out | 8.06M |
EPS (ttm) | -0.14 |
PE Ratio | n/a |
Forward PE | 17.64 |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | January 15 |
Last Price | $5.87 |
Previous Close | $5.98 |
Change ($) | -0.11 |
Change (%) | -1.84% |
Day's Open | 6.00 |
Day's Range | 5.70 - 6.09 |
Day's Volume | 116,644 |
52-Week Range | 4.10 - 7.96 |
News
TAMPA, FL, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Trxade Group, Inc. ( MEDS ) an integrated drug procurement, delivery and healthcare platform, today announced that management will present at the D...
Trxade Group Inc. (NASDAQ: MEDS) shares jumped on Tuesday after the company announced that it entered into a definitive agreement with Amazon.com Inc.
Shares of Trxade Group Inc. soared 56% in active trading to pace all of the premarket's gainers Tuesday, after the online platform for pharmaceutical purchases announced a market program agree...
About MEDS
Trxade Group, together with its subsidiaries, owns and operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc.; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services. Its principal products and services include Trxade.com, a web-based pharmaceutical marketplace; InventoryRx.co... [Read more...]
Industry Pharmaceutical Retailers | IPO Date Feb 13, 2020 |
CEO Surendra K. Ajjarapu | Employees 29 |
Stock Exchange NASDAQ | Ticker Symbol MEDS |
Analyst Forecasts
According to 3 analysts, the average rating for Trxade Group stock is "Buy." The 12-month stock price forecast is 12.17, which is an increase of 107.33% from the latest price.